129 related articles for article (PubMed ID: 25247668)
1. Anti-PD-1-targeted therapies focusing on lymphatic malignancies: biological rationale, clinical challenges and opportunities.
Kedmi M; Avigdor A; Nagler A
Acta Haematol; 2015; 133(2):129-35. PubMed ID: 25247668
[TBL] [Abstract][Full Text] [Related]
2. Blocking tumor escape in hematologic malignancies: the anti-PD-1 strategy.
Bryan LJ; Gordon LI
Blood Rev; 2015 Jan; 29(1):25-32. PubMed ID: 25260226
[TBL] [Abstract][Full Text] [Related]
3. Programmed death-1 immune checkpoint blockade in the treatment of hematological malignancies.
Tsirigotis P; Savani BN; Nagler A
Ann Med; 2016 Sep; 48(6):428-439. PubMed ID: 27224873
[TBL] [Abstract][Full Text] [Related]
4. Targeting immune checkpoints in hematological malignancies.
Salik B; Smyth MJ; Nakamura K
J Hematol Oncol; 2020 Aug; 13(1):111. PubMed ID: 32787882
[TBL] [Abstract][Full Text] [Related]
5. Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities.
Merelli B; Massi D; Cattaneo L; Mandalà M
Crit Rev Oncol Hematol; 2014 Jan; 89(1):140-65. PubMed ID: 24029602
[TBL] [Abstract][Full Text] [Related]
6. Use of CAR-T cell therapy, PD-1 blockade, and their combination for the treatment of hematological malignancies.
Song W; Zhang M
Clin Immunol; 2020 May; 214():108382. PubMed ID: 32169439
[TBL] [Abstract][Full Text] [Related]
7. Immune Dysfunction in Non-Hodgkin Lymphoma: Avenues for New Immunotherapy-Based Strategies.
Falchi L
Curr Hematol Malig Rep; 2017 Oct; 12(5):484-494. PubMed ID: 28822058
[TBL] [Abstract][Full Text] [Related]
8. Releasing the Brake on the Immune System: The PD-1 Strategy for Hematologic Malignancies.
Bryan LJ; Gordon LI
Oncology (Williston Park); 2015 Jun; 29(6):431-9. PubMed ID: 26091677
[TBL] [Abstract][Full Text] [Related]
9. Notch-ing from T-cell to B-cell lymphoid malignancies.
Mirandola L; Comi P; Cobos E; Kast WM; Chiriva-Internati M; Chiaramonte R
Cancer Lett; 2011 Sep; 308(1):1-13. PubMed ID: 21652011
[TBL] [Abstract][Full Text] [Related]
10. Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy.
Hamid O; Carvajal RD
Expert Opin Biol Ther; 2013 Jun; 13(6):847-61. PubMed ID: 23421934
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint inhibition in lymphoid disease.
Eyre TA; Collins GP
Br J Haematol; 2015 Aug; 170(3):291-304. PubMed ID: 25824455
[TBL] [Abstract][Full Text] [Related]
12. [Immune-checkpoint inhibitors in hematologic malignancies].
Maruyama D
Rinsho Ketsueki; 2016; 57(11):2381-2387. PubMed ID: 27941289
[TBL] [Abstract][Full Text] [Related]
13. [Impact of VEGF-A in exhaustion of intratumoral T cells].
Voron T; Tartour É; Taieb J; Terme M
Med Sci (Paris); 2015 May; 31(5):473-5. PubMed ID: 26059293
[No Abstract] [Full Text] [Related]
14. Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity.
Ramsay AG
Br J Haematol; 2013 Aug; 162(3):313-25. PubMed ID: 23691926
[TBL] [Abstract][Full Text] [Related]
15. Programmed death-1 expression in cutaneous B-cell lymphoma.
Çetinözman F; Koens L; Jansen PM; Willemze R
J Cutan Pathol; 2014 Jan; 41(1):14-21. PubMed ID: 24151955
[TBL] [Abstract][Full Text] [Related]
16. Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors.
Charmsaz S; Scott AM; Boyd AW
Exp Hematol; 2017 Oct; 54():31-39. PubMed ID: 28751189
[TBL] [Abstract][Full Text] [Related]
17. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
Allard B; Pommey S; Smyth MJ; Stagg J
Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
[TBL] [Abstract][Full Text] [Related]
18. Programmed death 1 and B and T lymphocyte attenuator immunoreceptors and their association with malignant T-lymphoproliferative disorders: brief review.
Karakatsanis S; Bertsias G; Roussou P; Boumpas D
Hematol Oncol; 2014 Sep; 32(3):113-9. PubMed ID: 24038528
[TBL] [Abstract][Full Text] [Related]
19. Combination epigenetic and immunotherapy overcomes resistance to monoclonal antibodies in hematologic malignancies: A new therapeutic approach.
Epner EM; Saroya BS; Hasanali ZS; Loughran TP
Exp Hematol; 2016 Mar; 44(3):157-60. PubMed ID: 26802532
[TBL] [Abstract][Full Text] [Related]
20. Combined blockade of programmed death-1 and activation of CD137 increase responses of human liver T cells against HBV, but not HCV.
Fisicaro P; Valdatta C; Massari M; Loggi E; Ravanetti L; Urbani S; Giuberti T; Cavalli A; Vandelli C; Andreone P; Missale G; Ferrari C
Gastroenterology; 2012 Dec; 143(6):1576-1585.e4. PubMed ID: 22929808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
